神经元特异性烯醇化酶在新生儿高胆红素血症的临床观察

目的：观察高胆红素血症新生患儿治疗前、后血清神经元特异性烯醇化酶（NSE）的变化,探讨其临床意义.方法：选择高胆红素血症新生患儿190例,观察组按总胆红素（TSB）分轻、中、重度3组,正常新生儿60例作为对照组,检测治疗前、后血清NSE和TSB.结果：治疗前,观察组血清NSE水平高于对照组（10.2±2.8）ng/ml,差异有统计学意义P＜0.05）.治疗后,观察组NSE下降,与治疗前比较差异有统计学意义（P＜0.05）：轻度组治疗后（11.0±4.5） ng/ml低于治疗前（19.9±4.1）ng/ml;中度组治疗后（10.8±4.8）ng/ml低于治疗前（29.1±6.2）ng/ml;重度组治疗后（14.9±6.8）ng/ml低于治疗前（37.5±7.6）ng/ml.结论：血清NSE是判断新生儿高胆红素血症严重程度和转归的生物学指标.

Clinical observation of neuron-specific enolase in neonatal hyperbilirubinemia

Objective： To observe the changes of neuron-specific enolase （NSE） in patients with neonatal hyperbilirubinemia before and after treatment and to explore their clinical significance. Methods： In observation group, 190 cases of neonatal hyperbilirubinemia were divided into light, medium or severe 3 groups based on total serum bilirubin （TSB）. Meanwhile, 60 normal neonates were obtained as control. The level of serum NSE and TSB were separately detected before and after treatment. Results： Results： Before treatment, the serum NSE level of observation group was higher than that of the control group （10.2±2.8）ng/ml, the difference was statistically significant （P〈0. 05）. After treatment, the observation group NSE decreased, compared with that before treatment, there was a statistically significant difference（P〈0. 05）; mild group after treatment （11.0±4.5）ng/ml, lower than that before treatment （19.9±4.1）ng/ml; moderate group after treatment （10.8±4.8）ng/ml, lower than that before treatment （29.1±6.2）ng/ml; severe group after treatment （14.9±6.8）ng/ml, lower than that before treatment （37.5±7.6）ng/ml. Conclusion： Serum NSE could be used to judge the severity and prognosis of neonatal hyperbilirubinemia biological index.